Navigation Links
StemCyte Locates East Coast Operations in New Jersey

Cell Therapy Company's Move Driven by Commitment of Governor and

Collaboration with Leading Stem Cell Researcher

EWING, N.J., May 1 /PRNewswire/ -- StemCyte Inc. today announced that it has located its East Coast operations in Ewing, N.J.

The move, which was supported by a Business Employment Incentive Program (BEIP) grant through the New Jersey Economic Development Authority, puts StemCyte's executives in close proximity to one of the company's collaborators: world-renowned spinal cord injury researcher Wise Young, M.D., Ph.D., at Rutgers University.

"The research being done by Dr. Young at Rutgers is top-notch," said Kenneth J. Giacin, chairman and chief executive officer of StemCyte. "In addition, Governor Corzine's plan for developing New Jersey as an active hub for stem cell research and therapeutics development was an important reason for our decision to move our East Coast operations to the state. We're pleased to become an integral part of New Jersey's life sciences community with our focus on therapies derived from umbilical cord blood."

In addition to the New Jersey location, StemCyte's operations are in California and Taiwan. The company is also developing StemCyte India Therapeutics in collaboration with Apollo Hospitals and Cadila Pharmaceuticals.

About StemCyte Inc.

StemCyte Inc. is a global cell therapy company with a focus on umbilical cord blood stem cells. Since 2001, the company's stem cell products have been used to successfully treat more than 600 patients suffering from life- threatening diseases and conditions. StemCyte also has a leadership position in the development of new cell therapies in high growth areas with the greatest clinical need. The company is accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). For more information, visit

StemCyte Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

David Schull

(212) 845-4271

SOURCE StemCyte Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millstone Medical Outsourcing Relocates Memphis Distribution Center Within 72 Hours of Tornado Disaster
2. Caliper Life Sciences Reports West Coast Consolidation of Operations
3. Phlo Affiliate to Launch AQUISS(TM) on East Coast
4. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
5. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Biopure Operations Compliant With U.K. Manufacturing Guidelines
9. Genta Restructures Operations to Focus on Priority Initiatives
10. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
11. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):